Glycopyrrolate · GLYCOPYRROLATE .2 mg/mL · Solution · Intramuscular; Intravenous · Somerset Therapeutics, LLC
NDC 70069-0618-25 · 25 VIAL in 1 CARTON / 2 mL in 1 VIAL · ANDA · View full market →
13 companies supply this market — deep enough that no single failure threatens the supply. One of its named manufacturing plants, Somerset Therapeutics Private Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
OAI inspection at a producing facility (24 months) · sole-source market · 1 Class I/II recall(s) in 12 months
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Somerset Therapeutics, LLC | GLYCOPYRROLATE .2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Ajenat Pharmaceuticals Llc | GLYCOPYRROLATE 1 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Atlantic Biologicals Corp. | GLYCOPYRROLATE 1 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | GLYCOPYRROLATE 1 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Bionpharma Inc. | GLYCOPYRROLATE 1 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | GLYCOPYRROLATE 1 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | GLYCOPYRROLATE 1 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Chartwell RX, LLC | GLYCOPYRROLATE 1 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Granules Pharmaceuticals Inc. | GLYCOPYRROLATE 1 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| NorthStar RxLLC | GLYCOPYRROLATE 1 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Par Health USA, LLC | GLYCOPYRROLATE 1 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Precision Dose, Inc. | GLYCOPYRROLATE 1 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Saptalis Pharmaceuticals, LLC. | GLYCOPYRROLATE 1 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Glycopyrrolate — NDC 70069-0618-25," retrieved September 3, 2026, https://drugdashboards.com/drug/70069061825.
Free to cite with attribution — see how the data is put together.